BioSpace News Archive

VIDA Diagnostics, Inc., the leader in AI-powered lung imaging analysis, announced the appointment of Erkan Akyuz as independent director.

Fare reductions begin October 5, providing easy access to Metro Boston’s public bike share system during construction

Cyclo Therapeutics, Inc. (OTCQB: CTDH) announced today that it has completed its name change from CTD Holdings, Inc. following appropriate regulatory filings with the State of Florida and FINRA.

Thousands of genomics and genetics researchers, professors, doctors, genetic counselors, nurses, and others from around the world will gather in Houston, Texas, October 15-19, for ASHG 2019, to share their latest research about the benefits of human genetics and genomics research, one of the fastest growing fields of modern health care development.

The Medicines Company (NASDAQ:MDCO) announced that it will participate in the Chardan 3rd Annual Genetic Medicines Conference on Tuesday, October 8, 2019, in New York.

Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced that it has closed an oversubscribed, non-brokered financing, raising approximately $7 million in proceeds.

Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, announced that it will report third quarter 2019 results on Tuesday, October 22, 2019, before the market opens

Health Canada is advising Canadians that LinkGlobal Food Inc. in Richmond Hill, Ontario, is recalling unauthorized “Yunnan Baiyao Toothpaste” because it is labelled to contain a prescription drug (tranexamic acid) and may pose serious health risks.

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced data from pooled analyses demonstrating the long-term benefit of the once-daily 40 mg dose of INGREZZA® (valbenazine) capsules in reducing abnormal movements in adults with tardive dyskinesia (TD), a potentially irreversible and often persistent involuntary movement disorder.

AIDS Healthcare Foundation (AHF) today is calling on Gilead Sciences Inc., one of the largest manufacturers of HIV/AIDS drugs, for a major price reduction on its HIV/AIDS treatment medication Descovy, the drug company’s fixed-dose combination of emtricitabine (FTC) and tenofovir alafenamide (TAF), for its use now also as pre-exposure prophylaxis or PrEP to prevent HIV acquisition in uninfected individuals.